The study is part of an effort to drive health plan coverage for Exosome's ExoDx Prostate IntelliScore prostate cancer test.
The partners will collaborate on clinical studies aimed at driving health plan coverage for molecular diagnostic products.
The funds will support a variety of business activities including diagnostic test development and the advance of new methods for tissue-specific exosome isolation.
The moves underscore a growing belief in industry and academia that the cell-derived vesicles could be the biomarker of choice for next-generation tests and therapies.
The Swiss biopharmaceutical company said it undertook both deals to develop new therapeutic and diagnostic applications based around exosomes.
Exosome Dx will help further Merck's drug development efforts in oncology and other areas using its exosome-based nucleic acid and protein detection technology.
The company developed the instrument using in-licensed technology coupled with its own chemistry and other technology for exosomal protein analysis.
The deal follows a June agreement under which Exosome is developing an exosomal RNA sequencing platform with Takeda.
A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.
Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.
Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.
In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.